CIITA Human shRNA Lentiviral Particle (Locus ID 4261)

CAT#: TL313899V

CIITA - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL313899A virus into HEK293 cells. TL313899A virus was prepared using lenti-shRNA TL313899A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL313899B virus into HEK293 cells. TL313899B virus was prepared using lenti-shRNA TL313899B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL313899C] virus into HEK293 cells. [TL313899C] virus was prepared using lenti-shRNA [TL313899C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL313899D] virus into HEK293 cells. [TL313899D] virus was prepared using lenti-shRNA [TL313899D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 4261
• Synonyms: C2TA; CIITAIV; MHC2TA; NLRA
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_000246, NM_001286402, NM_001286403, NR_104444, NM_000246.1, NM_000246.2, NM_000246.3, NM_001286403.1, NM_001286402.1, BC172348, BM193016, NM_001286403.2
• UniProt ID: P33076
• Summary: This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the "master control factor" for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).